News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,459 Results
Type
Article (50755)
Company Profile (281)
Press Release (687423)
Section
Business (213819)
Career Advice (2206)
Deals (36844)
Drug Delivery (108)
Drug Development (83963)
Employer Resources (175)
FDA (16990)
Job Trends (15771)
News (361618)
Policy (34949)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2792)
Accelerated approval (2)
Adcomms (23)
Allergies (83)
Alliances (51773)
ALS (86)
Alzheimer's disease (1410)
Antibody-drug conjugate (ADC) (113)
Approvals (16982)
Artificial intelligence (248)
Autoimmune disease (15)
Automation (14)
Bankruptcy (378)
Best Places to Work (12133)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (192)
Bladder cancer (59)
Brain cancer (25)
Breast cancer (258)
Cancer (2018)
Cardiovascular disease (157)
Career advice (1851)
Career pathing (30)
CAR-T (142)
Cell therapy (402)
Cervical cancer (19)
Clinical research (67836)
Collaboration (786)
Compensation (449)
Complete response letters (21)
COVID-19 (2727)
CRISPR (35)
C-suite (214)
Cystic fibrosis (99)
Data (1919)
Decentralized trials (2)
Denatured (28)
Depression (43)
Diabetes (249)
Diagnostics (6565)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (110)
Drug pricing (104)
Drug shortages (30)
Duchenne muscular dystrophy (88)
Earnings (89020)
Editorial (36)
Employer branding (21)
Employer resources (149)
Events (117312)
Executive appointments (651)
FDA (18116)
Featured Employer (49)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (708)
Gene editing (98)
Generative AI (24)
Gene therapy (281)
GLP-1 (741)
Government (4714)
Grass and pollen (4)
Guidances (48)
Healthcare (19970)
Huntington's disease (22)
IgA nephropathy (21)
Immunology and inflammation (107)
Indications (27)
Infectious disease (2861)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (48)
Intellectual property (84)
Interviews (341)
IPO (16942)
IRA (41)
Job creations (4073)
Job search strategy (1579)
Kidney cancer (9)
Labor market (34)
Layoffs (468)
Leadership (16)
Legal (8544)
Liver cancer (73)
Lung cancer (296)
Lymphoma (130)
Machine learning (2)
Management (58)
Manufacturing (280)
MASH (63)
Medical device (14331)
Medtech (14336)
Mergers & acquisitions (20369)
Metabolic disorders (662)
Multiple sclerosis (71)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (28)
Neuroscience (1900)
NextGen: Class of 2025 (6947)
Non-profit (4753)
Northern California (2407)
Now hiring (37)
Obesity (364)
Opinion (222)
Ovarian cancer (72)
Pain (80)
Pancreatic cancer (77)
Parkinson's disease (136)
Partnered (18)
Patents (204)
Patient recruitment (95)
Peanut (48)
People (60387)
Pharmaceutical (70)
Pharmacy benefit managers (20)
Phase I (21100)
Phase II (29798)
Phase III (22277)
Pipeline (973)
Podcasts (63)
Policy (112)
Postmarket research (2780)
Preclinical (8973)
Press Release (69)
Prostate cancer (93)
Psychedelics (33)
Radiopharmaceuticals (257)
Rare diseases (363)
Real estate (6338)
Recruiting (67)
Regulatory (23686)
Reports (46)
Research institute (2492)
Resumes & cover letters (370)
Rett syndrome (3)
RNA editing (2)
RSV (39)
Schizophrenia (68)
Series A (123)
Series B (80)
Service/supplier (13)
Sickle cell disease (50)
Southern California (2088)
Special edition (15)
Spinal muscular atrophy (153)
Sponsored (30)
Startups (3848)
State (2)
Stomach cancer (13)
Supply chain (62)
The Weekly (32)
United States (21382)
Vaccines (701)
Venture capitalists (38)
Webinars (12)
Weight loss (256)
Women's health (37)
Worklife (15)
Date
Today (125)
Last 7 days (575)
Last 30 days (2757)
Last 365 days (34508)
2025 (7860)
2024 (36253)
2023 (41305)
2022 (52533)
2021 (57254)
2020 (56090)
2019 (49000)
2018 (37117)
2017 (33974)
2016 (33856)
2015 (39847)
2014 (33601)
2013 (28865)
2012 (31159)
2011 (31844)
2010 (30235)
Location
Africa (820)
Alabama (50)
Alaska (7)
Arizona (234)
Arkansas (14)
Asia (41336)
Australia (6854)
California (5511)
Canada (1867)
China (484)
Colorado (254)
Connecticut (273)
Delaware (127)
Europe (89740)
Florida (815)
Georgia (200)
Idaho (61)
Illinois (530)
India (23)
Indiana (295)
Iowa (9)
Japan (139)
Kansas (103)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (861)
Massachusetts (4188)
Michigan (214)
Minnesota (381)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (58)
New Hampshire (67)
New Jersey (1583)
New Mexico (29)
New York (1585)
North Carolina (987)
North Dakota (7)
Northern California (2407)
Ohio (196)
Oklahoma (14)
Oregon (34)
Pennsylvania (1248)
Puerto Rico (9)
Rhode Island (28)
South America (1208)
South Carolina (19)
South Dakota (1)
Southern California (2088)
Tennessee (94)
Texas (824)
Utah (168)
Virginia (132)
Washington D.C. (61)
Washington State (523)
West Virginia (3)
Wisconsin (49)
738,459 Results for "zynex medical holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Zynex Recognized in Top 25 Medical Device Companies for 2024
Zynex, Inc. announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024.
February 2, 2024
·
1 min read
Business
Zynex Sets First Quarter 2024 Earnings Call
Zynex, Inc. will hold a conference call on Tuesday, April 30, 2024 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2024.
April 18, 2024
·
1 min read
BioMidwest
Zynex to Participate in Fireside Chat with RBC Capital Markets on Thursday, June 13, 2024
Zynex, Inc. announced that it will participate in an analyst-led fireside chat on an RBC Capital Markets 2024 Medical Device Strategy & Innovation Call at 11:00 AM ET on Thursday, June 13, 2024.
June 10, 2024
·
1 min read
Zynex Introduces New Products
Zynex, Inc. introduced two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression.
February 20, 2024
·
1 min read
Press Releases
Zynex Announces Open Oximetry Project Membership
December 4, 2024
·
5 min read
Business
Zynex Reports First Quarter 2024 Financial Results
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2024.
April 30, 2024
·
12 min read
Zynex to Present at the RBC Capital Markets Global Healthcare Conference
Zynex, Inc. announced it will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held May 14-15, 2024.
May 9, 2024
·
1 min read
Business
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
Zynex, Inc. will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023.
February 22, 2024
·
1 min read
Press Releases
Zynex Announces Completion of Its Laser Pulse Oximetry Trial
December 6, 2024
·
4 min read
Business
Zynex, Inc Sets Third Quarter 2023 Earnings Call
Zynex, Inc. (NASDAQ: ZYXI) will hold a conference call on Thursday, October 26, 2023 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2023.
October 12, 2023
·
1 min read
1 of 73,846
Next
